⚠️ This study is no longer recruiting participants. This information is provided for reference purposes only.
CALM2 Study: Testing New Nerve-Targeting Medications for Chronic Cough
The CALM2 study investigated new nerve-targeting medications for patients suffering from persistent chronic cough that has lasted for a year or more. This trial aimed to provide relief for those who had not found success with standard cough treatments.
Eligibility Criteria
- Age: 18-80 years
- Persistent cough for ≥ 1 year prior to screening
- Diagnosis of Refractory/Unexplained Chronic Cough (RCC/UCC)
- Cough Severity VAS ≥ 40 mm at screening and Day 1
- Chest X-ray or CT thorax within 5 years showing no significant abnormality
- Women: Must use highly effective contraception throughout the study
- Men: Must agree to no sperm donation for 3 months and use condoms during the study
Exclusion Criteria
- Current smoker or quit smoking < 6 months ago, or 20 pack-year history
- Diagnosis of COPD, bronchiectasis, idiopathic pulmonary fibrosis, or other significant respiratory disorders
- Uncontrolled asthma
- Incomplete cough evaluation for gastroesophageal reflux, rhinitis.
Study Outcomes
This study has concluded enrollment and is in the data analysis phase. For information about current or upcoming clinical trials for chronic cough, please contact our research team.